Alex Nemiroff - 08 Jan 2026 Form 4 Insider Report for Praxis Precision Medicines, Inc. (PRAX)

Reporting relationship: General Counsel and Secretary
Issuer ticker: PRAX
Reported as of: 08 Jan 2026
Net transaction value: -$264,509
SEC form: 4
Accepted by SEC: 12 Jan 2026, 17:49:56 UTC
Prior SEC filing: 09 Jan 2026
Next SEC filing: 13 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Alex Nemiroff

Key filing fact

Alex Nemiroff filed Form 4 for Praxis Precision Medicines, Inc. (PRAX) on 12 Jan 2026.

Key facts

This page summarizes Alex Nemiroff's Form 4 filing for Praxis Precision Medicines, Inc. (PRAX).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 12 Jan 2026, 17:49.

Change

Previous filing in this sequence was filed on 09 Jan 2026.
Current net transaction value: -$264,509.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001827760 Primary reporting owner

Nemiroff Alex

Relationship: General Counsel and Secretary
Address: C/O PRAXIS PRECISION MEDICINES, INC., 99 HIGH STREET, 30TH FLOOR, BOSTON
Signature: /s/ Alex Nemiroff
Signature date: 12 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PRAX transaction

Common Stock

Award

Transaction value: $0
Shares: +6,875
Change %: +33%
Price: $0.000000
Shares after: 27,618
Date: 08 Jan 2026
Ownership: Direct
Footnotes: F1

PRAX transaction

Common Stock

Tax liability

Transaction value: $264,509
Shares: -917
Change %: -3.3%
Price: $288.45
Shares after: 26,701
Date: 10 Jan 2026
Ownership: Direct
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PRAX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +5,500
Change %
Price: $0.000000
Shares after: 5,500
Date: 08 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 5,500
Exercise price: $294.38
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Mr. Nemiroff was awarded 6,875 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. The restricted stock units vest in equal annual installments over a four-year period beginning on the one-year anniversary of the vesting commencement date of January 8, 2026. The restricted stock units may be settled only by delivering shares of the Issuer's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.

Footnote F2

Shares withheld by the Issuer to satisfy the tax withholding obligations in connection with the vesting of certain previously reported restricted stock units.

Footnote F3

The shares underlying this stock option vest over a four-year period, with 25% vesting on January 8, 2027 and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the reporting person's continued service through each vesting date.